Literature DB >> 11533158

In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells.

W Lu1, J M Andrieu.   

Abstract

Despite significant immune recovery with potent highly active antiretroviral therapy (HAART), eradication of human immunodeficiency virus (HIV) from the bodies of infected individuals represents a challenge. We hypothesized that an inadequate or inappropriate signal in virus-specific antigen presentation might contribute to the persistent failure to mount efficient anti-HIV immunity in most HIV-infected individuals. Here, we conducted an in vitro study with untreated (n = 10) and HAART-treated (n = 20) HIV type 1 (HIV-1) patients which showed that pulsing of monocyte-derived dendritic cells (DC) with aldrithiol-2-inactivated autologous virus resulted in the expansion of virus-specific CD8(+) T cells which were capable of killing HIV-1-infected cells and eradicating the virus from cultured patient peripheral blood mononuclear cells independently of the disease stages and HAART response statuses of the patients. This in vitro anti-HIV effect was further enhanced by the HIV protease inhibitor indinavir (at a nonantiviral concentration), which has been shown previously to be able to up-regulate directly patient T-cell proliferation following immune stimulation. However, following a 2-day treatment with culture supernatant derived from immune-activated T cells (which mimics an in vivo environment of HIV-disseminated and immune-activated lymphoid tissues), DC lost their capacity to present de novo inactivated-virus-derived antigens. These findings provide important information for understanding the establishment of chronic HIV infection and indicate a perspective for clinical use of DC-based therapeutic vaccines against HIV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533158      PMCID: PMC114463          DOI: 10.1128/JVI.75.19.8949-8956.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  T-cell apoptosis in HIV-1-infected individuals receiving highly active antiretroviral therapy.

Authors:  T Böhler; K M Debatin; U Wintergerst
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

2.  Equivalent amplification of intrinsically variable nucleic acid sequences by multiple-primer-induced overlapping amplification assay: applications for universal detection and quantitation.

Authors:  W Lu; L Cao; L Ty; M Arlie; J M Andrieu
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

3.  Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease.

Authors:  R Salerno-Gonçalves; W Lu; J M Andrieu
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression.

Authors:  H Hatano; S Vogel; C Yoder; J A Metcalf; R Dewar; R T Davey; M A Polis
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

Review 5.  Prospective views of HIV pathology. Clues for therapeutic strategies.

Authors:  W Lu; J M Andrieu
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

6.  Multi-target PCR analysis by capillary electrophoresis and laser-induced fluorescence.

Authors:  W Lu; D S Han; J Yuan; J M Andrieu
Journal:  Nature       Date:  1994-03-17       Impact factor: 49.962

7.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

Authors:  Z Zhang; T Schuler; M Zupancic; S Wietgrefe; K A Staskus; K A Reimann; T A Reinhart; M Rogan; W Cavert; C J Miller; R S Veazey; D Notermans; S Little; S A Danner; D D Richman; D Havlir; J Wong; H L Jordan; T W Schacker; P Racz; K Tenner-Racz; N L Letvin; S Wolinsky; A T Haase
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

8.  Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Authors:  S Grabar; V Le Moing; C Goujard; C Leport; M D Kazatchkine; D Costagliola; L Weiss
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

9.  HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism.

Authors:  W Lu; J M Andrieu
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

10.  Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

Authors:  S M Santini; C Lapenta; M Logozzi; S Parlato; M Spada; T Di Pucchio; F Belardelli
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  18 in total

1.  Tat(28-35)SL8-specific CD8+ T lymphocytes are more effective than Gag(181-189)CM9-specific CD8+ T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay.

Authors:  John T Loffredo; Eva G Rakasz; Juan Pablo Giraldo; Sean P Spencer; Kelly K Grafton; Sarah R Martin; Gnankang Napoé; Levi J Yant; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape.

Authors:  John T Loffredo; Benjamin J Burwitz; Eva G Rakasz; Sean P Spencer; Jason J Stephany; Juan Pablo Giraldo Vela; Sarah R Martin; Jason Reed; Shari M Piaskowski; Jessica Furlott; Kim L Weisgrau; Denise S Rodrigues; Taeko Soma; Gnankang Napoé; Thomas C Friedrich; Nancy A Wilson; Esper G Kallas; David I Watkins
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

3.  A therapeutic dendritic cell-based vaccine for HIV-1 infection.

Authors:  Felipe García; Núria Climent; Lambert Assoumou; Cristina Gil; Nuria González; José Alcamí; Agathe León; Joan Romeu; Judith Dalmau; Javier Martínez-Picado; Jeff Lifson; Brigitte Autran; Dominique Costagliola; Bonaventura Clotet; Josep M Gatell; Montserrat Plana; Teresa Gallart
Journal:  J Infect Dis       Date:  2011-01-13       Impact factor: 5.226

4.  Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

Authors:  Adam J Gehring; Muzlifah Haniffa; Patrick T Kennedy; Zi Zong Ho; Carolina Boni; Amanda Shin; Nasirah Banu; Adeline Chia; Seng Gee Lim; Carlo Ferrari; Florent Ginhoux; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

5.  Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.

Authors:  Elizabeth Miller; Meredith Spadaccia; Rachel Sabado; Elena Chertova; Julian Bess; Charles Mac Trubey; Rose Marie Holman; Andres Salazar; Jeffrey Lifson; Nina Bhardwaj
Journal:  Vaccine       Date:  2014-11-15       Impact factor: 3.641

6.  Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses.

Authors:  Winni De Haes; Stefaan De Koker; Charlotte Pollard; Derek Atkinson; Erika Vlieghe; Jessy Hoste; Joanna Rejman; Stefaan De Smedt; Johan Grooten; Guido Vanham; Ellen Van Gulck
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

Review 7.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

Review 8.  Dendritic cell dysregulation during HIV-1 infection.

Authors:  Elizabeth Miller; Nina Bhardwaj
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

9.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

Review 10.  Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection.

Authors:  Tracy L Lehman; Kevin P O'Halloran; Edward A Hoover; Paul R Avery
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.